Antengene Corp (6996.HK) Stock Price

Antengene Corp Price

HKEX·CLOSED
2.82
​
Market closed

Revenue has compounded at 51.2% per year over the past 7 years to 122.65 M CNY. Antengene Corp's net margin stands at -227.0%, up from -2,278.6% several years earlier. Analysts set a median price target of 6.30 CNY, implying 123.4% above the current price. Of 9 analysts, 7 rate the stock a buy — an overall Buy consensus.

Antengene Corp stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Antengene Corp business model & stock analysis

Antengene Corp. Ltd. generates revenue through the development and commercialization of biopharmaceutical products, primarily targeting cancer treatments. The company focuses on ATG-010 (selinexor), which is used for relapsed/refractory multiple myeloma, diffuse large B-cell lymphoma, and non-small cell lung cancer, and ATG-008 (onatasertib), indicated for hepatocellular carcinoma and non-small cell lung cancer. These products are developed for the Asia-Pacific market, where the company conducts its main operations. The firm's revenue streams are derived from the clinical-stage development and eventual commercialization of these therapies, targeting healthcare providers and patients in the region. The company operates as a clinical-stage biopharmaceutical entity, emphasizing discovery, development, manufacturing, and commercialization of innovative cancer treatments. Its primary products, ATG-010 and ATG-008, are designed to address specific oncology indications, with a focus on relapsed or refractory conditions. The Asia-Pacific market serves as the core geographic segment for its business, where it aims to establish a strong presence through its pipeline of biotech products. Revenue is anticipated once these therapies advance through clinical trials and receive regulatory approvals for commercial use. Antengene Corp. Ltd. targets healthcare systems and oncology specialists in the Asia-Pacific region for its biopharmaceutical products. The company’s products are positioned for treatment of complex cancer types, with ATG-010 addressing multiple myeloma and lymphoma, and ATG-008 targeting liver and lung cancers. As a clinical-stage company, its current focus is on advancing these therapies through development stages, with commercialization expected to drive future revenue. The Asia-Pacific market remains central to its business strategy, where it leverages its regional presence to build partnerships and market access.

Frequently asked questions about Antengene Corp

Analysts currently set an average price target of 6.30 CNY for the Antengene Corp stock (median: 6.30 CNY), implying +162.0 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Antengene Corp stock: 7 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Antengene Corp to generate revenue of 823.93 M CNY and earnings per share of 0.48 CNY.

Converted at the current exchange rate, the Antengene Corp share trades at 0.38 EUR (2.82 CNY).

The Antengene Corp share (6996.HK) is listed on 2 stock exchanges, including: Hongkong (HKEX) (6996.HK), Frankfurt (722.F).

The expected revenue of Antengene Corp is 823.93 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Antengene Corp is 303.38 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Antengene Corp is currently 5.88. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Antengene Corp stock.

The price-to-sales ratio (P/S) of Antengene Corp is currently 2.16. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Antengene Corp stock.

The Eulerpool Quality Score for Antengene Corp is 2/10.

The ISIN of Antengene Corp is KYG039571008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Antengene Corp is A2QHCZ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Antengene Corp is 6996.HK. The ticker symbol is used to trade Antengene Corp shares on the stock exchange.

Fair ValueTerminal
2.59 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
341,637.88 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Nov 20, 2020
ISIN
KYG039571008
Cusip
G03957100
Market capitalization
1.92 B CNYSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
6.31
P/Ee 2027
-9.56
P/Ee 2028
-7.36
P/Se
2.16
EV/EBIT
—
P/B Ratio
2.56
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-26.56 %
Last updated Nov 3, 2026, 12:21 AM

Antengene Corp Peer Group

Antengene Corp Ticker

FRANKFURT · 722.FHKEX · 6996.HK

Antengene Corp FIGI

6996:HK · BBG00Y4731M5722:TH · BBG010H4NZ44722:GR · BBG010JWLT46722:GF · BBG010JWLT55722:GS · BBG010JWLT8269961EUR:X2 · BBG010WX88Q669961EUR:XH · BBG010WX88S469961EUR:XF · BBG010WX88V069961EUR:XE · BBG010WX88X869961EUR:XL · BBG010WX88Z669961EUR:XG · BBG010WX890269961EUR:XO · BBG010WX8911